Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, January 19, 2011
Tue, January 18, 2011 VITA, REGN, CRNT, WMGI, HSII, JNS Are Seasonally Ripe To Go Down In the Next Five Weeks
January 18, 2011 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of ORTHOVITA INC (NASDAQ:VITA), REGENERON PHARMACEUTICALS (NASDAQ:REGN), CERAGON NETWORKS L (NASDAQ:CRNT), WRIGHT MEDICAL GROUP INC (NASDAQ:WMGI), HEIDRICK & STRUGGLES INTL (NASDAQ:HSII), JANUS CAPITAL GROUP INC (NYSE:JNS) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php
The following stocks are expected to go Down:
Symbol Company Expected Return Odds By The Following Date
VITA ORTHOVITA INC -5.890 % 90.00% (9 of 10) Monday, January 24th 2011
REGN REGENERON PHARMACEUTICALS -6.020 % 73.68% (14 of 19) Friday, January 28th 2011
CRNT CERAGON NETWORKS L -6.690 % 80.00% (8 of 10) Friday, February 11th 2011
WMGI WRIGHT MEDICAL GROUP INC -6.990 % 77.78% (7 of 9) Monday, February 21st 2011
HSII HEIDRICK & STRUGGLES INTL -7.110 % 72.73% (8 of 11) Thursday, February 3rd 2011
JNS JANUS CAPITAL GROUP INC -7.150 % 90.00% (9 of 10) Thursday, February 3rd 2011
ORTHOVITA INC (NASDAQ:VITA) - Orthovita, Inc., a specialty spine and orthopedic company, develops and markets orthobiologic and biosurgery products. The companys orthobiologics platform offers products for the fusion, regeneration, and fixation of human bone; and the biosurgery platform provides products for controlling intra-operative bleeding/hemostasis. Its orthobiologic product portfolio comprises Vitoss bone graft substitute, a high-porous resorbable beta-tricalcium phosphate bone graft substitute used to help the body guide the three-dimensional regeneration of the patients own bone; Bone Marrow Aspiration System with imbibe needles, syringes, and imbibe disposable delivery instrumentation, which provides spine and orthopedic surgeons with a method for harvesting a patients own bone marrow; Cortoss Bone Augmentation Material, a polymer composite for use in various surgical procedures to provide structural stability and reinforcement of the bones after surgery; and Aliquot Delivery System that facilitates delivery of materials to bony sites, including delivery of Cortoss product directly to the surgical site. The companys biosugery products include Vitagel surgical hemostat, a composite liquid hemostat that combines the biomaterials bovine thrombin and bovine collagen with the patients autologous plasma, and applied in the spine, hip, and knee replacement surgeries; and Vitasure Absorbable Hemostat, a plant-based hemostat product that can be deployed throughout surgery. It sells its products in the United States and internationally through a network of direct sales representatives and independent non-stocking distributors. The company has strategic partnerships with Kensey Nash Corporation; Angiotech Pharmaceuticals (U.S.), Inc.; and Medafor, Inc. Orthovita was founded in 1992 and is headquartered in Malvern, Pennsylvania.
REGENERON PHARMACEUTICALS (NASDAQ:REGN) - Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States. The companys commercial product includes ARCALYST (rilonacept) injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its products under Phase III clinical trials include Rilonacept for the prevention and treatment of gout-related flares; VEGF Trap-Eye for eye diseases using intraocular delivery; and Aflibercept for the treatment of oncology. The companys earlier stage clinical programs REGN475, an antibody to nerve growth factor, which is being developed for the treatment of pain; REGN88, an antibody to the interleukin-6 receptor, which is developed in rheumatoid arthritis; REGN421, an antibody to delta-like ligand-4, for the treatment of oncology; REGN727, an antibody to proprotein convertase substilisin/kexin type 9, which is developed for low density lipoprotein cholesterol reduction; and REGN668, an antibody to the interleukin-4 receptor for certain allergic and immune conditions. Regeneron Pharmaceuticals also conducts other preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company has strategic collaboration with sanofi-aventis Group to discover, develop, and commercialize fully human monoclonal antibodies; and Bayer HealthCare LLC for the development of the VEGF-Trap-Eye. Regeneron Pharmaceuticals was founded in 1988 and is based in Tarrytown, New York.
CERAGON NETWORKS L (NASDAQ:CRNT) - Ceragon Networks Ltd. (Ceragon), incorporated on July 23, 1996, designs, develops, manufactures and sells high-capacity, point-to-point wireless backhaul solutions for cellular operators, fixed operators and private networks and enterprises. The Company's products operate over multiple frequency bands of up to 60 gigahertz, including frequencies that are licensed by various countries in North America, Europe, Middle East, Africa, Latin America and the Asia-Pacific region for use by the end customer and some that are unlicensed. Ceragon primarily targets fixed and mobile communications service providers and private networks and enterprises that require high capacity connectivity. Its products have been commercially deployed in approximately 70 countries by service providers and private customers, including local telephone companies and cellular telephone service operators and corporate organizations. Products are sold through a direct sales force, systems integrators, distributors and original equipment manufacturers.
Products
Ceragon's product consists of an outdoor unit, an indoor unit, a compact antenna and a network management system. The antenna transmits and receives microwave radio signals. The outdoor unit controls the power transmission, converts intermediate frequency (IF) signals to radio frequency (RF) signals and vice versa, and provides an interface between the antenna and the indoor unit. The outdoor unit is enclosed in a compact weatherproof enclosure, which is fastened to the antenna. The antenna is mounted on a pole, which is typically mounted on a rooftop, tower or the side of a building. The indoor unit is connected to the outdoor unit by a standard coaxial cable.
Ceragon markets its products under the trademark FibeAir. The FibeAir products utilize multiple modulation schemes and give service providers the ability to choose between increased range and increased spectral efficiency. The FibeAir family of products includes FibeAir 1500P, FibeAir IP-Max, FibeAir 1500HP, FibeAir 3200T, FibeAir 10060 and FibeAir 4800.
The FibeAir 1500P system provides from 155 to 622 megabits per second of transmission capacity for various interfaces using single or dual independent, hot swappable carriers with optional cross-polar interference canceller (XPIC) mechanism. The FibeAir IP-Max is Ceragon's new wireless native ethernet solution. The system provides from 50 to 800 megabits per second of transmission capacity for fast ethernet and gigabit-ethernet interfaces combined with bandwidth allocation of time division multiplexing (TDM) interfaces. The FibeAir 1500HP is the Company's long-haul wireless system. The system operates in the frequency range of 6 to 11 gigahertz and is equipped with built-in XPIC, software configurable modulation allowing quadrature phase-shift keying (QPSK) and 32 to 256 quadrature amplitude modulation (QAM) and configurable bandwidth from 10 to 40 megahertz. The FibeAir 3200T provides wireless data transmission over long distances, in a variety of network capacities, frequencies and configurations. The FibeAir 10060 system provides full rate gigabit ethernet (1.25 gigabits per second) transmission capacity over a license-exempt, 60-gigahertz channel. The FibeAir 4800 system is designed to provide up to 48 megabits per second of aggregate capacity over license-exempt channels in the 2.4-gigahertz to 5.85-gigahertz range.
Ceragon provides network management based on simple network management protocol (SNMP) to support its products. Its management applications include CeraView, a SNMP-based elementary management system (EMS) that enables the operator to perform element configuration, RF and synchronous digital hierarchy (SDH) performance monitoring, remote diagnostics and alarm reports, and PolyView, which is Ceragon's network management system server that includes CeraMap.
Services
Ceragon supports its products with documentation and training courses tailored to customers' various needs. Its sales and network field engineering services personnel work closely with customer
WRIGHT MEDICAL GROUP INC (NASDAQ:WMGI) - Wright Medical Group, Inc., an orthopaedic medical device company, designs, manufactures, and markets reconstructive joint devices and biologics products. The company also provides surgical solutions for the foot and ankle market. The reconstructive devices are used to replace knee, hip, and other joints and bones that have deteriorated or have been damaged through disease or injury; and biologics are used to replace damaged or diseased bone to stimulate bone growth and to provide other biological solutions for surgeons and their patients. The company offers products in the extremity reconstruction, biologics, knee reconstruction, and hip reconstruction market sectors. Wright Medical Group sells its products through a network of independent and commission-based sales representatives, as well as by a combination of employee sales representatives, independent sales representatives, and stocking distributors. It has operations in the United States, Asia, Europe, the Middle East, Africa, Latin America, and Canada. Wright Medical Group was founded in 1950 and is headquartered in Arlington, Tennessee.
HEIDRICK & STRUGGLES INTL (NASDAQ:HSII) - Heidrick & Struggles International, Inc. provides executive search and leadership consulting services in the Americas, Europe, and the Asia Pacific. It facilitates the recruitment, management, and deployment of senior executives. The companys leadership consulting services include succession planning, talent retention management, executive assessment, executive development, transition consulting for newly appointed executives, and M&A human capital integration consulting. Its customers include Fortune 1000 companies; the major non-U.S. companies; middle market and emerging growth companies; governmental, higher education, and not-for-profit organizations; and private and public entities. The company was founded in 1953 and is headquartered in Chicago, Illinois.
JANUS CAPITAL GROUP INC (NYSE:JNS) - Janus Capital Group, Inc. is a publicly owned asset management holding company with approximately $167.7 billion in assets under management. It also provides retirement planning, investment planning, tax planning, investment for college, and tax planning services to its clients. The firm primarily provides its services to investment companies, retail investors, institutions, and individuals. Through its subsidiaries, it manages equity, fixed income, money markets, and balanced mutual funds for its clients and invests in the public equity and fixed income markets across the globe. The firm was formerly known as Stilwell Financial Incorporated. Janus Capital Group was founded in 1969 and is based in Denver Colorado with additional offices in the United States, Hong Kong; London; Milan; and Tokyo, Japan.
SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com
www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.
INVESTMENTS & TRADING
SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
About SQUEEZETRIGGER.COM
WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.
SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.
All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.
Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.
By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.
Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.
Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.
Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com
SqueezeTrigger is a registered trademark, Reg. No. 3,120,641
- WOPRAI
- support@woprai.com